Role and challenges of proteomics in pharma and biotech: technical, scientific and commercial perspective.
Contemporary proteomics, currently in its exponential growth phase, is a bewildering array of tools. Proteomic methods are the result of a convergence of rapidly improving mass spectrometry technologies, protein chemistry and separation sciences, genomics and bioinformatics. Strides in improving proteomics technologies to map and measure proteomes and subproteomes are being made. However, no single proteomic platform appears ideally suited to address all research needs or accomplish ambitious goals satisfactorily. However, proteomics is in a unique position to contribute to protein discovery and to public health in terms of better biomarkers, diagnostics and treatment of disease. While the potential is great, many challenges and issues remain to be solved. Fundamental issues, such as biological variability, pre-analytic factors and analytical reproducibility, remain to be resolved. Neither an all-genetic approach nor an all-proteomic approach will solve biological complexity. Proteomics will be the foundation for constructing and extracting useful knowledge to pharma and biotech depicted in the following path: data --> structured data --> information --> information architecture --> knowledge --> useful knowledge.
Qoronfleh
M Walid
MW
Core Technology Alliance CTA, University of Michigan, Ann Arbor, MI 48109-1274, USA. walidq@umich.edu
D000818:Animals; D015415:Biomarkers; D001709:Biotechnology / Q000379:methods*; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D013058:Mass Spectrometry; D011506:Proteins / Q000737:chemistry / Q000378:metabolism; D040901:Proteomics / Q000191:economics* / Q000379:methods*
D015415:Biomarkers; D011506:Proteins